SecBot SecBot

RNA

Atrium Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0002093101 Biotech & Drug Discovery
$8.14 −0.06 (−0.73%)
Oct 26 4:00 PM ET · prev $8.20
Market cap
$139.6M
Micro cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
$25.00
+207% · range $15.00–25.00
Since first trade
−37.4%
from $13.01 · Jul 6
30 days
−3.3%
from $8.42
Range since listing
$7.61–14.60
−44% from high · low Oct 19
Avg volume 20D
250.4K
Oct 8 spike 645.6K
Short interest
3.40M
≈19.9% of shares · −0.1%
Days to cover
8.3
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
Reddit crowd
50°
Neutral · 2 mentions this week
SecBot read BEARISH 7 reports · 90 days
Balance 1 bearish · 0 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 5/7
Strongest BEARISH Atrium Therapeutics announced a ~$50M private placement, selling 5,170,384 common shares at $7.93/share and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 10 added (0 new), 17 trimmed or exited.

  • AnalystsBULLISH

    7 of 8 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.700 → −$0.630 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −0.1% to 3.40M shares. 8.3 days to cover, ≈19.9% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 2 mentions: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
Squarepoint Ops LLCTRIM146,743$2.0M
TUDOR INVESTMENT CORP ET ALADD129,591$1.7M
ExodusPoint Capital Management, LPADD117,275$1.6M
JANE STREET GROUP, LLCDOUBLED109,810$1.5M
BALYASNY ASSET MANAGEMENT L.P.TRIM105,875$1.4M
VANGUARD PORTFOLIO MANAGEMENT LLCTRIM101,195$1.4M
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM100,000$1.3M
Caption Management, LLCTRIM75,277$1.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 88% rate it Buy or better
Strong Buy2Buy5Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +207%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 22, 2026Roth Capital
INITIATE
INITIATEBuy
Aug 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 6, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Jun 18, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
May 15, 2026Leerink Partners
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 18, 2026
Boyce Sarah
Director
TAX W/H$1.1M
Sep 18, 2026
Flanagan W. Michael
Director
TAX W/H$204.2K
Sep 18, 2026
Younis Husam
Chief Scientific Officer
TAX W/H$100.4K
Sep 18, 2026
Hughes Steven George
Chief Medical Officer
TAX W/H$192.1K
Sep 18, 2026
Winslow Brendan R.
Chief Financial Officer
TAX W/H$60.3K
Sep 18, 2026
Gallagher Kathleen P.
See Remarks
TAX W/H$104.1K
Sep 18, 2026
Kenney Stephanie
See Remarks
TAX W/H$21.3K
Sep 18, 2026
Hoyos Rocio Martin
Chief Strategy Officer
TAX W/H$74.5K

Earnings setup

Estimates
−$0.63
EPS estimate, this quarter
+10%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.63-$0.67–-$0.59+6.0%$12.0M
Next Q-$1.37-$1.37–-$1.37+20.3%$400.0K
Current FY-$3.87-$4.12–-$3.61+15.1%$35.0M
Next FY-$5.96-$6.39–-$5.53+26.1%$1.6M
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 2 1 in posts · 1 in comments
Recent posts
r/pennystocks Neutral 1d ago
Three proteomics biotech penny stocks: NAUT, QSI and PACB
1 upvotes · 0 comments
Recent comments
r/wallstreetbets Neutral 2d ago
Seems like a perfectly reasonable change considering the technology has changed to include messenger RNA. What’s your point?
All social signals and their track records

Short side

FINRA· Sep 30, 2026
3,395,873
shares short
-0.1%
vs prior settlement
8.3
days to cover
≈19.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 Press
Atrium Therapeutics granted inducement stock options and restricted stock units to a new non-executive employee under…
Impact 2/10
Oct 20, 2026 Contract
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") tod
Oct 9, 2026 SEC
Atrium Therapeutics filed an 8-K/A to correct the share count disclosed in its October 8, 2026 original 8-K regarding…
8-K/A — Impact 2/10
Oct 8, 2026 SEC
Atrium Therapeutics announced a ~$50M private placement, selling 5,170,384 common shares at $7.93/share and pre-funded…
8-K — Impact 6/10
Sep 21, 2026 Press
Atrium Therapeutics granted inducement stock options and RSUs to one new non-executive employee under its 2026…
Impact 2/10
Sep 18, 2026 Insider
Boyce Sarah surrendered for taxes 126,418 shares
Director @ $8.95 ($1.1M)
Sep 18, 2026 Insider
Flanagan W. Michael surrendered for taxes 22,812 shares
Director @ $8.95 ($204.2K)
Sep 18, 2026 Insider
Younis Husam surrendered for taxes 11,216 shares
Chief Scientific Officer @ $8.95 ($100.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 20, 2026
Contract
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on…
Oct 12, 2026
Trial readout
Results Pending: AOC 1001 (del-desiran) (Phase 3) — Completed 81d ago
Trial: Global Study of Del-desiran for the Treatment of DM1 Sponsor: Avidity Biosciences, Inc. Phase: Phase 3 | Completed: 2026-07-23 Conditions…
Sep 28, 2026
Clinical Trial
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Phase 2 · COMPLETED
Sep 21, 2026
Contract
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on…
Sep 11, 2026
Clinical Trial
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Phase 2 · COMPLETED

SecBot reports

5 filings · 4 press releases · 1 bullish · 1 bearish · 3 neutral
All RNA filing & press-release reports (9)